Jupiter Neurosciences(JUNS.US)

Last Updated 19:00:00 ET
longbridge loading

Jupiter Neurosciences prices registered direct offering at USD 2 million

PUBT·
US
JUNS
-39.47%
PUBT·
US
JUNS
-39.47%

JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1

MSN·
US
JUNS
-39.47%
US
BBH
+0.68%
US
ARKG
+4.59%
MSN·
US
JUNS
-39.47%
US
BBH
+0.68%
US
ARKG
+4.59%

Jupiter Neurosciences shares are trading higher after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.

benzinga_article·
US
JUNS
-39.47%
US
IBB
+1.93%
US
BIB
+4.03%
benzinga_article·
US
JUNS
-39.47%
US
IBB
+1.93%
US
BIB
+4.03%

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | JUNS Stock News

StockTitan·
US
JUNS
-39.47%
US
VHT
+0.21%
US
FBT
+1.76%
StockTitan·
US
JUNS
-39.47%
US
VHT
+0.21%
US
FBT
+1.76%

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | JUNS Stock News

StockTitan·
US
JUNS
-39.47%
US
VHT
+0.21%
US
PBE
+1.37%
StockTitan·
US
JUNS
-39.47%
US
VHT
+0.21%
US
PBE
+1.37%
© 2026 Longbridge｜Disclaimer